RNA, U6 small nuclear 869, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-869P profile across patient tissues and cancer cell-line models. RNU6-869P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RNU6-869P is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, RNU6-869P RNA expression shows 5,421 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and KIRC as cancer lineages where RNU6-869P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-869P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-869P survival associations across molecular data types. RNU6-869P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-869P RNA expression–survival associations across cancer types. High RNU6-869P expression shows unfavorable associations in STAD, THCA, UVM and UCEC, but favorable associations in LGG and SKCM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RNU6-869P RNA expression.
This table summarizes RNU6-869P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-869P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-869P shows lower tumor expression in KIRC, BRCA, LUSC and KICH. The KIRC box plot shows higher RNU6-869P RNA expression in normal versus tumor tissue (log2 FC = −0.140, t-test p = .002).
This table shows molecular features associated with RNU6-869P in patient tissues and cancer cell lines. In patient samples, RNU6-869P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
